CD4 and systemic lupus erythematosus: Additionally, BL001 ́s anti‐inflammatory properties are highlighted by the inhibition of multiple enriched pathways related to inflammatory responses (systemic lupus erythematosus, influenza A, Epstein–Barr virus, among others), as well as pathways involved in either cell cycle or cellular senescence in BL001‐treated M10. These molecular events translated to the inhibition of CD4+ T‐cell proliferation.